N/A
N=29
Non-pharmaceutical Motion Sickness Mitigation
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT04859868 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Motion Perception — 55.3; 49.7; 50.1 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Galvanic Vestibular Stimulation (Device)
- Age
- Adult · 21+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Aug 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Motion Perception |
55.3; 49.7; 50.1 | — |
| SECONDARY Motion Sickness Questionnaire |
3.0; 3.2; 3.4 | — |
Summary
The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.
Eligibility Criteria
Inclusion Criteria
- Must be able to consent to participate themselves.
- Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ.
- No racial ethnic groups will be excluded.
- Must be fluent speakers of English.
Exclusion Criteria
- History of vestibular disease, migraine, or significant balance disorder.
- Traumatic brain injury.
- Recent middle ear infection or recent motion sickness (within 72 hours).
- History of severe motion sensitivity.
- Women who are pregnant.
Data sourced from ClinicalTrials.gov (NCT04859868). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.